Insilico Medicine and Liquid AI partner to build science‑oriented AI models for drug discovery
Insilico Medicine and Liquid AI announced a strategic partnership to co-develop lightweight scientific foundation models for drug discovery, targeting molecular representation, structure prediction and biological activity forecasting. The collaboration aims to reduce computational cost while improving predictive performance and will make initial models accessible to external researchers within months.
Why it mattersInsilico Medicine and Liquid AI will deliver lightweight foundation models, speeding target ID and lowering compute costs.
Entities Mentioned
Insilico MedicineLiquid AI